Compare Fidelity National Information Servcs Inc (FIS) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs 10X Genomics Inc — how do they compare? Fidelity National Information Servcs Inc trades at $34.36 (market cap $17.44B), while 10X Genomics Inc trades at $78.6 (market cap $9.92B). The key difference: Fidelity National Information Servcs Inc is the larger of the two by market cap, and Fidelity National Information Servcs Inc pays a 5.2% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and 10X Genomics Inc for 92 Days on average.
| FIS | TXG | |
|---|---|---|
Market Cap | $17.44B | $9.92B |
Volume | 6,437,765 | 9,372,166 |
Sector | Technology | Health |
52-Week High | $68.57 | $97.74 |
52-Week Low | $32.44 | $11.48 |
Typical Hold Time | 88 Days | 92 Days |
Enterprise Value | $37.95B | $9.44B |
Dividend Yield | 5.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.34, up 2.75% today, with a bearish technical signal despite recent earnings beats in Q1 and Q2 2026. The company shows improving fundamentals with revenue growth from $10.7B in 2025 to projected $12.2B in 2026 and strong profitability metrics including 27.65% net income margin. Recent news highlights strategic wins in core banking modernization and embedded finance platforms.
The stock presents a compelling value opportunity with a low P/E of 5.2 and analyst consensus target of $47.54 (38% upside), though risks include significant debt load and volatile cash flow trends. Institutional sentiment remains positive with 57% buy ratings, but technical weakness near key support at $33 requires monitoring.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
